PT  - JOURNAL ARTICLE
AU  - Buckely, Rita
ED  - Rosenstock, Julio
TI  - Long-Term Injection-Free Subcutaneous Delivery of Exenatide via ITCA 650 Improves Compliance and Controls Glycemic Parameters and Weight
DP  - 2011 Sep 01
TA  - MD Conference Express
PG  - 12--13
VI  - 11
IP  - 8
4099  - http://mdc.sagepub.com/content/11/8/12.short
4100  - http://mdc.sagepub.com/content/11/8/12.full
AB  - Exenatide therapy in patients with type 2 diabetes who take metformin requires twice-daily self-injections and is associated with significant nausea and vomiting [Pinelli NR, Hurren KM. Ann Pharmacother 2011]. Continuous delivery of exenatide was evaluated in a Phase 2, randomized study with ITCA 650, a subcutaneous osmotic delivery system that provides constant delivery of exenatide at specified doses [ITCA 650; NCT00943917].